What is Wedbush's Estimate for Disc Medicine Q2 Earnings?

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush cut their Q2 2025 earnings per share estimates for Disc Medicine in a report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.02) per share for the quarter, down from their prior forecast of ($0.91). Wedbush currently has a "Outperform" rating and a $90.00 price target on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine's Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.20) EPS, FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at $5.68 EPS and FY2029 earnings at $8.88 EPS.

Several other brokerages have also recently issued reports on IRON. TD Cowen started coverage on Disc Medicine in a report on Thursday, February 27th. They set a "buy" rating for the company. Scotiabank upped their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Morgan Stanley restated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. BMO Capital Markets upped their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday. Finally, Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $98.80.

Disc Medicine Stock Performance

IRON stock traded up $2.37 during midday trading on Friday, hitting $46.61. 465,322 shares of the stock were exchanged, compared to its average volume of 350,137. The stock's 50-day moving average price is $46.72 and its 200-day moving average price is $54.99. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -11.71 and a beta of 0.77. Disc Medicine has a fifty-two week low of $30.65 and a fifty-two week high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently added to or reduced their stakes in the business. FMR LLC lifted its position in Disc Medicine by 358.7% during the fourth quarter. FMR LLC now owns 1,866,248 shares of the company's stock worth $118,320,000 after buying an additional 1,459,434 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Disc Medicine by 23.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock worth $88,421,000 after acquiring an additional 262,690 shares during the last quarter. Vanguard Group Inc. increased its stake in Disc Medicine by 22.2% during the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company's stock worth $64,782,000 after acquiring an additional 236,800 shares during the last quarter. Janus Henderson Group PLC increased its stake in Disc Medicine by 62.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock worth $77,170,000 after acquiring an additional 467,988 shares during the last quarter. Finally, Woodline Partners LP increased its stake in Disc Medicine by 5.2% during the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock worth $25,144,000 after acquiring an additional 19,538 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $87,873.80. Following the transaction, the chief operating officer now directly owns 40,555 shares in the company, valued at approximately $2,213,491.90. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 5,574 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $304,228.92. Following the transaction, the chief executive officer now owns 154,828 shares in the company, valued at $8,450,512.24. This trade represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 356,290 shares of company stock worth $19,336,901. 4.24% of the stock is owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.